Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Reich who wrote (21274)	4/23/1999 5:03:00 PM
From: RT	Read Replies (1) \| Respond to of 23519

Joe, Funny but true. Leland cost investors roughly 32 million in 18 minutes. Thanks LEE. RT

To: Joe Reich who wrote (21274)	4/23/1999 5:09:00 PM
From: VLAD	Respond to of 23519

Joe, As far as Vivus spending on marketing: At this point the only near term spending planned will be on 1)the AUA conference May 1st in Dallas and 2)individual mailings to doctors who are known to be writing prescriptions for Viagra. IMO this is a very efficient method of targeting just the doctors who are treating ED with Viagra and may want to know about a much safer alternative for the at risk group. The information is obtained from individual prescriptions written that the various pharmacies fill. IMO it is a very conservative and efficient marketing technique. I think it will be even more effective when the s### hits the fan concerning the Viagra safety concerns once the media gets hold of the annual adverse reaction report. If the doctors who already prescribe Viagra know about MUSE in advance they can then be educated and prepared to offer a safe alternative to either their CVD patients or patients that simply will be scared to use Viagra after that annual report gets publicized.